Expanding the chemical nature of siRNAs: Oxaliplatin as metalation reagent

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 186-190

  Snygg, Åse Sykfont ^a   Elmroth, Sofi K C ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Down regulation; MALDI ToF MS; Melting temperature; Oxaliplatin; Platinum; r(GpG) adduct; siRNA

Indexed keywords

LUCIFERASE; MESSENGER RNA; METAL COMPLEX; OXALIPLATIN; REAGENT; SMALL INTERFERING RNA; WNT5A PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; COMPLEX FORMATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; MELTING POINT; METALLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE; HUMANS; LUCIFERASES; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RNA STABILITY; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSITION TEMPERATURE; WNT PROTEINS;

EID: 58249109705     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.068     Document Type: Article

References (34)

1. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8 (2007) 23-36
2. Wu L., and Belasco J.G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol. Cell 29 (2008) 1-7
3. Kim D.H., and Rossi J.J. RNAi mechanism and applications. Biotechniques 44 (2008) 613-616
4. Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell 122 (2005) 17-20
5. Schwarz D.S., Hutvagner G., Du T., Xu Z.S., Aronin N., and Zamore P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115 (2003) 199-208
6. Khvorova A., Reynolds A., and Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115 (2003) 209-216
7. Fedorov Y., Anderson E.M., Birmingham A., Reynolds A., Karpilow J., Robinson K., Leake D., Marshall W.S., and Khvorova A. Off-target effects by siRNA can induce toxic phenotype. RNA 12 (2006) 1188-1196
8. Hagerlof M., Hedman H., and Elmroth S.K.C. Platination of the siRNA sense-strand modulates both efficacy and selectivity in vitro. Biochem. Biophys. Res. Commun. 361 (2007) 14-19
9. Takahara P.M., Frederick C.A., and Lippard S.J. Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J. Am. Chem. Soc. 118 (1996) 12309-12321
10. Takahara P.M., Rosenzweig A.C., Frederick C.A., and Lippard S.J. Crystal-structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377 (1995) 649-652
11. Kankia B.I., Soto A.M., Burns N., Shikiya R., Tung C.S., and Marky L.A. DNA oligonucleotide duplexes containing intramolecular platinated cross-links: energetics, hydration, sequence, and ionic effects. Biopolymers 65 (2002) 218-227
12. Poklar N., Pilch D.S., Lippard S.J., Redding E.A., Dunham S.U., and Breslauer K.J. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc. Natl. Acad. Sci. USA 93 (1996) 7606-7611
13. Hagerlof M., Papsai P., Hedman H.K., Jungwirth U., Jenei V., and Elmroth S.K.C. Cisplatin and siRNA interference with structure and function of Wnt-5a mRNA: design and in vitro evaluation of targeting AU-rich elements in the 3′ UTR. J. Biol. Inorg. Chem. 13 (2008) 385-399
14. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 4 (2005) 307-320
15. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Can. Therapeut. 1 (2002) 227-235
16. Kasparkova J., Vojtiskova M., Natile G., and Brabec V. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. Eur. J. 14 (2008) 1330-1341
17. Hah S.S., Sumbad R.A., de Vere White R.W., Turteltaub K.W., and Henderson P.T. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol. 20 (2007) 1745-1751
18. Leandersson K., Riesbeck K., and Andersson T. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res. 34 (2006) 3988-3999
19. Dejmek J., Leandersson K., Manjer J., Bjartell A., Emdin S.O., Vogel W.F., Landberg G., and Andersson T. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin. Cancer Res. 11 (2005) 520-528
20. E.G. Richards, Use of tables in calculation of absorption, optical rotary dispersion and circular dichroism of polyribonucleotides, third ed., in:G.D.Fasman(Ed.), CRC Handbook of Biochemistry and Molecular Biology: Nucleic Acids,vol. 1, CRC Press, Cleveland, OH, 1975, pp. 596-603.
21. Marky L.A., and Breslauer K.J. Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves. Biopolymers 26 (1987) 1601-1620
22. Kirpekar F., Douthwaite S., and Roepstorff P. Mapping posttranscriptional modifications in 5S ribosomal RNA by MALDI mass spectrometry. RNA 6 (2000) 296-306
23. Douthwaite S., and Kirpekar F. Identifying modifications in RNA by MALDI mass spectrometry 425 (2007)
24. Bartek J., Bartkova J., Kyprianou N., Lalani E.N., Staskova Z., Shearer M., Chang S., and Taylorpapadimitriou J. Efficient immortalization of luminal epithelial-cells from human mammary-gland by introduction of simian virus-40 large tumor-antigen with a recombinant retrovirus. Proc. Natl. Acad. Sci. USA 88 (1991) 3520-3524
25. (Ala). Dalton. Trans. (2006) 3515-3517
26. Lenz A., Cordes F., Heinemann U., and Saenger W. Evidence for a substrate-binding subsite in ribonuclease-T1-crystal-structure of the complex with 2 guanosines, and model-building of the complex with the substrate guanylyl-3′,5′-guanosine. J. Biol. Chem. 266 (1991) 7661-7667
27. Gohda K., Oka K., Tomita K., and Hakoshima T. Crystal-structure of Rnase T1 complexed with the product 3'-GMP-structural evidence for direct interaction of histidine-40 and glutamic-acid-58 with the 2'-hydroxyl group of the ribose. J. Biol. Chem. 269 (1994) 17531-17536
28. http://library.med.utah.edu/masspec/mongo.ht.
29. Fichtinger-Schepman A.M.J., Vanderveer J.L., Denhartog J.H.J., Lohman P.H.M., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA - formation, identification, and quantitation. Biochemistry 24 (1985) 707-713
30. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 22 (1983) 3927-3933
31. Eastman A. Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 24 (1985) 5027-5032
32. Eastman A. Reevaluation of Interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25 (1986) 3912-3915
33. Fan X.H.C., and Steitz J.A. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc. Natl. Acad. Sci. USA 95 (1998) 15293-15298
34. Barreau C., Paillard L., and Osborne H.B. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 33 (2005) 7138-7150